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article under the CC BY-NC-ND licenseAbstract Objective: To explore the effect of 3-dimensional (3D) printing-assisted cognitive
fusion on improvement of the positive rate in prostate biopsy.
Methods: From August to December 2014, 16 patients with suspected prostatic lesions de-
tected by multiparametric magnetic resonance imaging (MRI) were included. Targeted pros-
tate biopsy was performed with the use of prostate 3D reconstruction modeling, computer-
simulated biopsy, 3D printing, and cognitive fusion biopsy. All patients had received 3.0 T mul-
tiparametric MRI before biopsy. The DICOM MRI files were imported to medical imaging proces-
sing software for 3D reconstruction modeling to generate a printable .stl file for 3D printing
with use of transparent resin as raw material. We further performed a targeted 2- to 3-core
biopsy at suspected lesions spotted on MRI.
Results: For the 16 patients in the present study, 3D modeling with cognitive fusion-based tar-
geted biopsy was successfully performed. For a single patient, 1e2 lesions (average: 1.1 le-
sions) were discovered, followed by 2e6 cores (average: 2.4 cores) added as targeted
biopsy. Systematic biopsies accounted for 192 cores in total, with a positive rate of 22.4%; tar-
geted biopsies accounted for 39 cores in total, with a positive rate of 46.2%. Among these
cases, 10 patients (62.5%) were diagnosed with prostate adenocarcinoma, in which seven were
discovered by both systematic and targeted biopsy, one was diagnosed by systematic biopsy
only, and two were diagnosed by targeted biopsy only. For systematic biopsy, Gleason score
ranged from 6 to 8 (average: 7), while that for targeted biopsy ranged from 6 to 9 (average:
7.67). Among the seven patients that were diagnosed by both systematic and targeted biopsy,
three (42.8%) were reported with a higher Gleason score in targeted therapy than in systematic
biopsy.om.cn (Y. Sun).
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3D printing assisted cognitive fusion in prostate biopsy 215Conclusion: 3D printing-assisted cognitive fusion technique markedly promoted positive rate in
prostate biopsy, and reduced missed detection in high-risk prostate cancer.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Transrectal ultrasound (TRUS) guided prostate biopsy is the
first choice in the diagnosis of prostate cancer [1]. How-
ever, the traditional method has difficulty in avoiding
missed diagnosis, for as high as 22%e47% of prostate cancer
are missed in the initial biopsy [2]. The standard TRUS
guided prostate biopsy is mainly for sampling in the pe-
ripheral zone where the incidence of cancer is high, but this
conventional approach is poor in sampling cancers at the
anterior, midline, and apex of the prostate, leading to un-
derdiagnosis of clinically significant diseases [3]. Magnetic
resonance imaging (MRI) has higher sensitivity in finding
clinically significant prostate cancer [4]. Functional MRI
technique as dynamic contrast-enhancement (DCE) and
diffusion weighted imaging (DWI) may provide more accu-
rate space orientation on the basis of qualitative diagnosis.
It has now become an important problem regarding the use
of image positioning to guide prostate biopsy so as to
effectively improve the biopsy positive rate in the early
diagnosis of prostate cancer. MRI-TRUS fusion targeted
biopsy and MRI-guided targeted biopsy are effective ap-
proaches to improve biopsy positive rate and avoid missed
diagnosis of prostate cancer [5,6], but both have higher
requirement for hardware facilities, and need complicated
skills in operation; therefore, it is rather difficult to apply
these methods in conventional examination.
Currently, 3-dimensional (3D) printing technique is
fast developing and has infiltrated into multiple in-
dustries including healthcare industry. Now its applica-
tion in medical field is mainly in implant design, surgery
simulation, skill training and others. There has not been
much report from urinary surgery in this regard. This
study explores 3D printing technique assisting cognitive
fusion for design of prostate biopsy regimen, and evalu-
ates its feasibility and efficacy in improvement of posi-
tive rate of prostate biopsy.
2. Patients and methods
2.1. Patients
This prospective study was conducted in the Changhai
Hospital Affiliated to Second Military Medical University
(Shanghai, China). The code of ethics was reviewed by the
Institutional Review Board of Changhai Hospital and
approval was obtained. Informed consents were obtained
from patients eligible for this study, and any potential
harms and benefits regarding to the study were elaborated.
Study enrollment began in 2014.2.2. Multi-parameter MRI examination
All patients had received 3.0 T multiparametric MRI
(Siemens Magnetom Skyra, Germany) before biopsy. The
scan sequence included T1 weighted, T2 weighted, DCE and
DWI. Two radiologists identified and located lesions suspi-
cious for cancer according to the MRI sequences (Fig. 1A).
Both radiologists were blinded to pre-imaging serum pros-
tate specific antigen (PSA) values and digital rectal exam-
ination (DRE) status.
2.3. 3D reconstruction and 3D printing
Digital Imaging and Communications in Medicine (DICOM)
format file of MRI was introduced into medical image pro-
cessing software accordingly. Prostate and tumor images
were introduced for 3D model reconstruction and smoothly
processed to generate printable .stl format files (Fig. 1B,C).
By means of SLA, RS-450, 3D printer, the .stl files were
printed in accordance with a thickness of 0.1 mm. The
printing material was transparent resin (Fig. 1D).
2.4. Systematic prostate biopsy
All patients received 12-core systematic prostate biopsy
under TRUS guidance. The 12-core biopsy was performed on
the basis of the traditional 6-core biopsy by adding three
cores on both sides of the lateral peripheral zones.
2.5. Targeted biopsy under 3D printing assisted
cognitive fusion
The suspected lesions found by multi-parametric MRI
further underwent a targeted 2e3-core biopsy. Before bi-
opsy, the location of the suspected focus in the prostate
was determined according to the 3D reconstruction data,
followed by computer simulation 12-needle systematic bi-
opsy performed (Fig. 2A) to estimate whether the sus-
pected focus could be detected in the course of biopsy. If
the suspected focus was in the anterior, midline, and apex,
because of the limitations of biopsy angle or biopsy depth,
systematic biopsy might not be able to take samples. Then
computer simulation of targeted biopsy procedures
(Fig. 2B) should be done to select biopsy sections, needling
angles and needling depth at triggering.
3. Results
From August to December, 2014, 16 patients (median age 64
years) successfully underwent 3D modeling with cognitive
fusion-based targeted biopsy. Patient and biopsy
Figure 1 Prostate 3-dimensional (3D) model building and its printing based on multi-parametric magnetic resonance imaging
(MRI). The patient was male, PSA 16.2 ng/mL, with history of one prior negative biopsy. (A) Comparison of T2 weighted image with
dynamic condition for enhancement of image fusion, displaying the tumor location with an abnormal signal in the right side of the
central lobe of the prostate; (B) MRI data introduced into medical image processing platform for 3D model building; (C) The .stl
format file introduced into the software, indicating the special location of the tumor; (D) Transparent resin material used for 3D
printing model, the spatial structure of the tumor shown by staining in later phase.
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opsy was 14.95 ng/mL (range 1.11e33.35 ng/mL), and 14 of
16 (87.5%) patients had a negative DRE.
For a single patient, one to two lesions (average: 1.1
lesions) were discovered, followed by 2e6 cores (average:
2.4 cores) added as targeted biopsy. Eight patients had
suspected lesions in the peripheral zone, and the remaining
eight had lesions in atypical zones such as the prostate apex
and central gland. Systematic biopsies accounted for 192
cores in total, with a positive rate of 22.4%; targeted bi-
opsies accounted for 39 cores in total, with a positive rate
of 46.2%. No patient required hospitalization for fever or
sepsis after biopsy.
Of the 16 patients, 10 patients (62.5%) were diagnosed
with prostate adenocarcinoma (Table 2), in which seven
were discovered by both systematic and targeted biopsy,
one was diagnosed by systematic biopsy only, and two were
diagnosed by targeted biopsy only. For systematic biopsy,Gleason score ranged from 6 to 8 (average: 7), while that
for targeted biopsy ranged from 6 to 9 (average: 7.67).
Among the seven patients that were diagnosed by both
systematic and targeted biopsy, three (42.9%) were re-
ported with a higher Gleason score in targeted therapy than
in systematic biopsy.4. Discussion
How to effectively avoid false negative results in biopsy is
an important problem in the early diagnosis of prostate
cancer. The development of MRI techniques provides more
and more accurate localization diagnosis on the basis of its
qualitative diagnosis. With rational use of imaging locali-
zation information, performing targeted biopsy on sus-
pected cancer foci is an effective method to improve the
positive rate of diagnosis. At present, fusion technique
based on MRI-identified foci includes MRI/TRUS fusion, MRI/
Figure 2 Computer simulated prostate system and targeted biopsy. (A) Computer simulated transrectal 12-needle systematic
biopsy, showing that the conventional biopsy scheme is unable to sample in the suspected area; (B) Computer simulated targeted
biopsy on suspected area; (C) Selecting the sagittal plane on the right side of the central lobe as biopsy plane; (D) The biopsy
needle penetrated through the prostate envelope for 12e14 mm, followed by triggering and sampling in the suspected area.
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Artemis device to perform biopsy on 105 cases, in which PSA
continued to rise after initial negative biopsy. By perform-
ing subsequent targeted biopsy with MRI/TRUS fusion on
these cases, the positive rate was 34%. Of the positive
targeted biopsy cases, 91% were of clinical significance
(Gleason score 7), and that of systematic biopsy was 54%.
Hoeks et al. [6] performed MR-guided biopsy on patients
with elevated PSA and one or more previous negative TRUSTable 1 Patient demographics.
Indice Median Range
Age (year) 64 53e82
PSA (ng/mL) 14.95 1.11e33.35
Prostate volume (mL) 39 22e89
PSA density (ng/mL2) 0.373 0.028e0.744
Lesions of suspicion on MRI 1 1e2
Targeted biopsy cores 2 2e6
PSA, prostate specific antigen; MRI, magnetic resonance
imaging.biopsy sessions. In a total of 117 patients, cancer detection
rate was 41%, and the majority of detected cancers were
clinically significant (87%). The two methods are both able
to improve the positive rate and avoid missed diagnosis of
cancer in prostate biopsy, but requirements for image
fusion device are high, which was inconvenient to operate,
hence is not conducive to extended promotion on large
scale.
In cognitive fusion, the operator selects suspected re-
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218 Y. Wang et al.under TRUS guidance. Its efficacy is still in controversy.
Puech et al. [7] believed that the result of targeted biopsy
in terms of cognitive fusion is not obviously different from
that of systematic biopsy in terms of MRI/TRUS fusion;
Delongchamps et al. [8] thought that targeted biopsy by
cognitive fusion did not have obvious advantage over sys-
tematic biopsy (pZ 0.66). Cognitive fusion depends greatly
on the operator’s experience, which is easy and simple to
handle but without accurate methods. Its efficacy and
repeatability is relatively poor. Therefore, to improve
cognitive fusion method and raise its efficacy in prostate
biopsy is of high importance for the improvement of biopsy
positive rate and avoidance of missed diagnosis of high-risk
prostate cancer.
3D printing technique performs accurate modeling in
terms of multi-parameter MRI localization diagnostic in-
formation that makes use of computer software simulated
biopsy and objectively evaluates systematic biopsy capa-
bility in the diagnosis of the suspected areas. In conven-
tional systematic biopsy, the needle is triggered the
moment it touches the prostatic capsule. If the tumor is
located at the tip of the prostate or close to the urethra or
at other atypical areas, conventional systematic biopsy may
have difficulty in sampling these suspected areas; there-
fore, an individualized biopsy plan can be worked out in
terms of computer simulated needling angles and depths.
For the patients in the present study, 3D print assisting
cognitive fusion targeted biopsy avoided the missed diag-
nosis of two cases (20%), effectively improving the biopsy
positive rate. Besides, of the seven patients found with
cancer by both system and target biopsies, three (42.9%)
were with higher points of Gleason score by targeted biopsy
than by systematic biopsy; high-risk prostate cancer was
effectively found. Two patients in this group were found
with cancer only by targeted biopsy; both had a history of
one prior negative prostate biopsy, multi-parametric MRI
found suspected lesions in transition zone, thus it is clear
that this technique is of marked significance in the diag-
nosis of cancer in non-peripheral zones.
3D printing technique can accurately reproduce 3D
image, and application of transparent resin material can
intuitively show the location, size and morphology of the
tumor. Before biopsy, the operator can observe the 3D
model of the tumor from multiple angles, thus evaluating
the possibility of sampling by systematic biopsy. If the
suspected focus is located in the peripheral zone, sampling
can be done by systematic biopsy, for which the corre-
sponding needle position for transrectal 12-needle sys-
tematic biopsy would be determined. In cases of non-
peripheral zone and larger-sized cancers, it is impossible
for the biopsy needle to sample in the suspected area that
triggers the moment it touches the envelope of the pros-
tate. The needing depth can thus be adjusted so as to break
through the envelope and get close to the suspected area
prior to triggering. Each suspected area can be further
determined with 2e3 biopsies to avoid tumor omissions. In
this study, the single needle positive rate for targeted bi-
opsy was 46.2%, which was markedly higher than the 22.4%
one for systematic biopsy.
The application of 3D printing technique effectively
improves the efficacy of cognitive fusion, and avoids the
drawback of depending too much on the operator’sexperience. It is of certain accuracy and repeatability, but
there is still much room to be desired in this approach.
Firstly, the prostate is a soft tissue organ, so MRI data image
processing is more difficult than that for bone, teeth and
other tissues. In the data modeling phase, adequate
acknowledgment of pelvic anatomy is very much required.
With the assistance of the image practitioner, only by being
clear of the suspected area in MRI image, can one perform
relatively accurate modeling of the prostate and the sus-
pected focus. Secondly, prostate cancer is likely to be
characterized by multiple foci, so multi-parametric MRI
cannot find small-sized foci. Therefore, based on various
fusions of multi-parametric MRI, targeted biopsy cannot
take place of systematic biopsy completely. Development
of targeted biopsy relies on advances in more sensitive and
specific imaging technologies.
Currently, 3D printing technique is fast developing and
integrating in multiple industries including healthcare in-
dustry. Its major application in the medical field is now
involved in implant design, surgery simulation, training and
others [9,10]. There have been just a few 3D print appli-
cations in the urology field. Zhang et al. [11] reported
research on 3D printing technique applied in the planning of
renal tumor surgery and believed that it was of great sig-
nificance for doctor’s surgery planning and doctor-patient
communication. With its development and the advent of
new materials, this technology will surely be applied more
extensively in the urology surgery field.
5. Conclusion
The development of new technologies and their cross-
fusion with multi-discipline is an important driving force
for medical development. In this study, we applied 3D
printing technique assisting cognitive fusion in the early
diagnosis of prostate cancer, which markedly improved the
positive rate of biopsy and avoided missed diagnosis of
high-risk prostate cancer. This technical operation proves
to be easy and simple. The increased number of needling in
targeted biopsy does not increase the incidence of
complication. Its application and popularization will surely
benefit more patients on a larger scale in the future.
Conflicts of interest
The authors declare no conflict of interest.References
[1] Hodge KK, McNeal JE, Terris MK, Stamey TA. Random sys-
tematic versus directed ultrasound guided transrectal core
biopsies of the prostate. J Urol 1989;142:71e5.
[2] Taira AV, Merrick GS, Galbreath RW, Andreini H,
Taubenslag W, Curtis R, et al. Performance of transperineal
template-guided mapping biopsy in detecting prostate cancer
in the initial and repeat biopsy setting. Prostate Cancer
Prostatic Dis 2010;13:71e7.
[3] Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A,
Klotz L, et al. Image-guided prostate biopsy using magnetic
resonance imaging-derived targets: a systematic review. Eur
Urol 2013;63:125e40.
3D printing assisted cognitive fusion in prostate biopsy 219[4] Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, Crouzet S,
et al. Dynamic contrast-enhanced-magnetic resonance imag-
ing evaluation of intraprostatic prostate cancer: correlation
with radical prostatectomy specimens. Urology 2009;74:
1094e9.
[5] Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M,
Lieu P, et al. Value of targeted prostate biopsy using magnetic
resonance-ultrasound fusion in men with prior negative biopsy
and elevated prostate-specific antigen. Eur Urol 2014;65:
809e15.
[6] Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Huls-
bergen-van de Kaa CA, Hambrock T, et al. Three-Tesla mag-
netic resonance-guided prostate biopsy in men with increased
prostate-specific antigen and repeated, negative, random,
systematic, transrectal ultrasound biopsies: detection of
clinically significant prostate cancers. Eur Urol 2012;62:
902e9.
[7] Puech P, Rouviere O, Renard-Penna R, Villers A, Devos P,
Colombel M, et al. Prostate cancer diagnosis: multiparametricMR-targeted biopsy with cognitive and transrectal US-MR
fusion guidance versus systematic biopsyeprospective multi-
center study. Radiology 2013;268:461e9.
[8] Delongchamps NB, Peyromaure M, Schull A, Beuvon F,
Bouazza N, Flam T, et al. Prebiopsy magnetic resonance im-
aging and prostate cancer detection: comparison of random
and targeted biopsies. J Urol 2013;189:493e9.
[9] Cousley RR, Turner MJ. Digital model planning and comput-
erized fabrication of orthognathic surgery wafers. J Orthod
2014;41:38e45.
[10] Rohner D, Guijarro-Martinez R, Bucher P, Hammer B. Impor-
tance of patient-specific intraoperative guides in complex
maxillofacial reconstruction. J Craniomaxillofac Surg 2013;41:
382e90.
[11] Zhang Y, Ge HW, Li NC, Yu CF, Guo HF, Jin SH, et al. Evaluation
of three-dimensional printing for laparoscopic partial ne-
phrectomy of renal tumors: a preliminary report. World J Urol
2015 Apr 5 [Epub ahead of print].
